The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study
Open Access
- 26 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Infectious Diseases
- Vol. 20 (1), 1-10
- https://doi.org/10.1186/s12879-020-4933-z
Abstract
Understanding factors driving virological failure, including the contribution of HIV drug resistance mutations (DRM), is critical to ensuring HIV treatment remains effective. We examine the contribution of drug resistance mutations for low viral suppression in HIV-positive participants in a population-based sero-prevalence survey in rural South Africa. We conducted HIV drug resistance genotyping and ART analyte testing on dried blood spots (DBS) from HIV-positive adults participating in a 2014 survey in North West Province. Among those with virologic failure (> 5000 copies/mL), we describe frequency of DRM to protease inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTI), and non-nucleoside reverse transcriptase inhibitors (NNRTI), report association of resistance with antiretroviral therapy (ART) status, and assess resistance to first and second line therapy. Analyses are weighted to account for sampling design. Overall 170 DBS samples were assayed for viral load and ART analytes; 78.4% of men and 50.0% of women had evidence of virologic failure and were assessed for drug resistance, with successful sequencing of 76/107 samples. We found ≥1 DRM in 22% of participants; 47% were from samples with detectable analyte (efavirenz, nevirapine or lopinavir). Of those with DRM and detectable analyte, 60% showed high–level resistance and reduced predicted virologic response to ≥1 NRTI/NNRTI typically used in first and second-line regimens. DRM and predicted reduced susceptibility to first and second-line regimens were common among adults with ART exposure in a rural South African population-based sample. Results underscore the importance of ongoing virologic monitoring, regimen optimization and adherence counseling to optimize durable virologic suppression.Funding Information
- US Centers for Disease Control and Prevention (5U2GGH000324-02)
This publication has 36 references indexed in Scilit:
- Design and Implementation of an External Quality Assessment Program for HIV Viral Load Measurements Using Dried Blood SpotsJournal of Clinical Microbiology, 2015
- HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis TrialThe Journal of Infectious Diseases, 2014
- High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South AfricaScience, 2013
- Increases in Adult Life Expectancy in Rural South Africa: Valuing the Scale-Up of HIV TreatmentScience, 2013
- Optimization of a Low Cost and Broadly Sensitive Genotyping Assay for HIV-1 Drug Resistance Surveillance and Monitoring in Resource-Limited SettingsPLOS ONE, 2011
- Prevention of HIV-1 Infection with Early Antiretroviral TherapyThe New England Journal of Medicine, 2011
- Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical modelThe Lancet, 2009
- In Vitro Human Immunodeficiency Virus Type 1 Resistance Selections with Combinations of Tenofovir and Emtricitabine or Abacavir and LamivudineAntimicrobial Agents and Chemotherapy, 2006
- An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adultsAIDS, 2006
- HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance.The Journal of Infectious Diseases, 2005